PROCEED® Surgical Mesh

Value Analysis Committee
PROCEED®
Surgical Mesh
Product
Information Kit
Create an IP
OM mesh o
for strength ptim
and perform ized
ance
Color sticky
note represen
ts customer
insight.
Third-party trademarks used herein are trademarks of their respective owners.

Table of Contents
Product Information
Trusted Surgical Mesh for Laparoscopic 3
and Open Ventral Hernia Repairs
Designed for Strength and Performance 4
Supports Safe and Comfortable Healing 5
Device Details 6
Sizes and Codes 7
Mesh Conversion Chart 8
Ordering Information 9
Instructions for Use 10
Regulatory Information
510(k) Clearance Letter 13
Clinical Evidence 16
References 23
Proceed®
Product Information Regulatory Information Clinical Evidence References
Trusted Solution for Laparoscopic Designed for Strength Supports Safe and Device Sizes and Mesh Conversion Ordering Instructions
and Open Ventral Hernia Repairs and Performance Comfortable Healing Details Codes Chart Information for Use
Trusted Solution
for Laparoscopic and Open
Intraperitoneal/Intra-abdominal
Ventral Hernia Repairs
PROCEED® Surgical Mesh is a macroporous,
partially absorbable, tissue-separating mesh
• Trusted by surgeons for over 10 years
• Designed for strength and performance
• Supports safe and comfortable healing
• In an in vitro study, PROCEED Mesh demonstrated
bacteriostatic properties against bacteria commonly
found in surgical site infections (MRSA, MRSE, VRE,
and E. coli)1*
*An in vitro study (24 hour study with inoculum challenge in the range of 105-106 CFU’s) demonstrated
bacteriostatic properties of PROCEED Mesh against MRSA, MRSE, VRE, and E. coli.
3
Trusted Solution for Laparoscopic and Designed for Strength Supports Safe and Device Sizes and Mesh Conversion Ordering Instructions
Open Ventral Hernia Repairs and Performance Comfortable Healing Details Codes Chart Information for Use
PROCEED® Surgical Mesh
Designed for Strength

and Performance
• Designed to withstand the maximum intra-abdominal pressure in healthy adults2-4*
800
620 mm Hg
700
(post-absorption)
600
Pressure (mm Hg)
500
400
300 252 mmHg
200
100
0
Standing Bench Press Valsalva Coughing Jumping PROCEED®
• Customizable5
– Can be trimmed based on surgeon’s discretion, while leaving sufficient overlap to help
prevent recurrence
• Blue stripes distinguish parietal side from visceral side5
• Versatility for both open and laparoscopic repairs5
– Pliable mesh can be rolled for laparoscopic deployment and placement
Open repair Laparoscopic repair

Laparoscopic "scroll" technique, as outlined in Saber AA.
Simple technique for mesh placement during laparoscopic
ventral hernia repair. Surg Endosc. 2004;18:162-164.
*Shown in a preclinical study
4
Supports Comfortable Healing

PROCEED® Surgical Mesh is built on Ethicon’s
Macroporous Partially Absorbable Mesh (MPPAM) technology
• Macroporous polypropylene layer5
– Promotes host tissue penetration and fibrin fixation of the mesh to the tissue, helping to eliminate
dead space and reduce risk of seroma formation3,6,7
– Allows patients to heal naturally5,8,9
• Absorbable tissue-separating barrier5*†
– Bioresorbable oxidized regenerated cellulose (ORC) layer on visceral side helps minimize
tissue attachment to mesh5*†
In a study from the International Hernia Mesh Registry (IHMR), patients receiving
open hernia repair with PROCEED Mesh reported significant improvement in pain
and movement limitations from baseline at 12 months postsurgery10‡
Patient Reported Hernia Pain at CCS Mean Movement Limitation
Baseline and 12-months Post Surgery Score and 95% CI
100 Baseline
5 Pre
12-months Post Surgery
4.5
80 1 Month
4
% of Patients
62% 3.5 6 Months^

CCS Score
60
3 12 Months~
2.5
40
31% 2
1.5
20 1
0.5
0 0
Time-Point Change from baseline:
^:-0.88(1.16SD) p<0.001; ~:-0.81(1.57) p<0.001
Results from a laparoscopic ventral hernia repair study showed low

rates of complications and hernia recurrence at 2-year follow-up11§
Postoperative Complication 2 Year Follow-Up Rate
Infection 0%
Pain or discomfort 4.7%
Recurrence 5.7%
*Data from an animal study

†PROCEED Mesh has an ORC component that should not be used in the presence of uncontrolled and/or active bleeding as fibrinous exudates may increase
the chance of adhesion formation.
‡Data from a prospective, longitudinal study of 82 patients receiving open hernia repair using PROCEED Mesh from the IHMR; 95.1% ventral hernias,
4.9% umbilical hernias; mesh placement: preperitoneal (n=40), intraperitoneal (n=40), retrorectus (n=1), onlay (n=1)
§Data from a multicenter prospective observational cohort study of 210 patients undergoing primary laparoscopic ventral hernia repair (n=97) or incisional
hernia repair using intra-abdominal placement of PROCEED Mesh
5
Device Details
PROCEED® Surgical Mesh is composed of three materials with distinct functions:
• PROLENE® Soft Polypropylene Mesh – nonabsorbable layer on the parietal side, as indicated by blue stripes,
provides strength and allows for tissue ingrowth5
• Oxidized regenerated cellulose (ORC) knitted fabric – plant-based material on the visceral side provides
a bioresorbable layer that physically separates the polypropylene mesh from underlying tissue and organ
surfaces during wound healing, to minimize tissue attachment; absorbed within 4 weeks5,12
Immediately Post Implantation 6 Hours Post Implantation

ORC forms a continuous gel by 6 hours
post-implantation that physically separates
the mesh from underlying tissues5
• PDS® (polydioxanone) Suture polymer film – creates a flexible, secure bond between the polypropylene
mesh and ORC; absorbed within 6 months5
Parietal Side
PDS Suture
polymer film
PROLENE
Soft Mesh
PDS Suture
polymer film
Oxidized regenerated
cellulose (ORC)
Visceral Side
PROCEED Mesh inhibits the growth of bacteria Proven in vitro bacteriostatic activity against:
commonly associated with surgical site infections
In an in vitro study, PROCEED Mesh demonstrated MRSA MRSE VRE E. coli
bacteriostatic properties against bacteria commonly found
in surgical site infections (MRSA, MRSE, VRE, and E. coli)13*
*An in vitro study (24 hour study with inoculum challenge in the range of 105-106 CFU’s) demonstrated
bacteriostatic properties of PROCEED Mesh against MRSA, MRSE, VRE, and E. coli.
6
Available in a Range of Sizes

Ordering Code Mesh Size Shape How Supplied
PCDB1 5 cm x 10 cm Rectangle Sterile, 1 per box
PCDR1 7.5 cm x 15 cm Rectangle Sterile, 1 per box
PCDN1 10 cm x 15 cm Oval Sterile, 1 per box
PCDM1 15 cm x 15 cm Square Sterile, 1 per box
PCDD1 10 cm x 20 cm Rectangle Sterile, 1 per box
PCDG1 15 cm x 20 cm Oval Sterile, 1 per box
PCDH1 20 cm x 25 cm Oval Sterile, 1 per box
PCDJ1 20 cm x 30 cm Rectangle Sterile, 1 per box
PCDT1 26 cm x 34 cm Oval Sterile, 1 per box
PCDW1 25 cm x 35.5 cm Rectangle Sterile, 1 per box
PCDL1 30.5 cm x 30.5 cm Square Sterile, 1 per box
How supplied
PROCEED® Surgical Mesh is available in single packets as sterile devices in a variety of sizes and shapes.
Indications for use

PROCEED Mesh may be used for the repair of hernias and other fascial deficiencies that require the addition
of a reinforcing or bridging material to obtain the desired surgical result.5
For complete indications, warnings,

precautions, and adverse reactions,
see pages 10-12.
See your Ethicon Sales Representative
for more information.
7
Mesh Conversion Chart

MEDTRONIC
BARD PARIETEX™
BARD VENTRALIGHT™ ST MEDTRONIC Optimized
PROCEED® VENTRALIGHT™ Mesh with Echo PS™ SYMBOTEX™ Composite (PCOx)
Surgical Mesh Size / Shape ST Mesh Positioning System Composite Mesh Mesh
PCDR1 7.5 cm x 15 cm 5954460 5955460 SYM1510 PCO1510X

(3” x 6”) 10.2 cm x 15.2 cm 10.2 cm x 15.2 cm SYM1510OS PCO1510FX
Rectangle 15 cm x 10 cm PCO1510OSX
15 cm x 10 cm
PCDN1 10 cm x 15 cm 5954460 5955460 SYM1510 PCO1510X

Oval 15 cm x 10 cm PCO1510OSX
15 cm x 10 cm
PCDM1 15 cm x 15 cm 5954600 5955600 SYM15 PCO15X

(6” x 6”) 15.2 cm 15.2 cm 15 cm PCO15FX
Square 15 cm
PCDG1 15 cm x 20 cm 5954680 5955680 SYM2015 PCO2015X

20 cm x 15 cm
PCDH1 20 cm x 25 cm 5954810 5955810 SYM2520 PCO2520X

25 cm x 20 cm
PCDJ1 20 cm x 30 cm 5954113 5955113 SYM3020 PCO3020X

(8” x 12”) 25.4 cm x 33 cm 25.4 cm x 33 cm SYM3020OS PCO3020FX
Rectangle 30 cm x 20 cm PCO3020OSX
30 cm x 20 cm
PCDT1 26 cm x 34 cm 5954113 5955113 SYM3728 PCO3728X

(10” x 13”) 25.4 cm x 33 cm 25.4 cm x 33 cm 37 cm x 28 cm PCO3728FX
Oval 37 cm x 28 cm
PCDW1 25 cm x 35.5 cm 5954113 5955113 SYM3728 PCO3728X

(10” x 14”) 25.4 cm x 33 cm 25.4 cm x 33 cm 37 cm x 28 cm PCO3728FX
Rectangle 37 cm x 28 cm
PCDL1 30.5 cm x 30.5 cm 5954124 5955124 SYM4024E PCO3728X

(12” x 12”) 30.5 cm x 35.6 cm 30.5 cm x 35.6 cm 40 cm x 24 cm PCO3728FX
Square 37 cm x 28 cm
The third-party trademarks used herein are trademarks of their respective owners.
8
Ordering Information
Product can be ordered direct through Johnson & Johnson Health Care Systems, Inc. (JJHS)
and through distributor channels.
Electronic ordering options

Note: Placing orders electronically avoids minimum order fees for hospitals.
Order 360™: order360.jnjgateway.com

For questions about your order, visit the website or call 1-866-565-4283.
Global Healthcare Exchange: ghx.com

For questions about your order, visit the website or call 1-800-YOUR-GHX.
Electronic Data Interchange

Call JJHCS EDI Help Line: 1-800-262-2888.
Nonelectronic/Manual ordering options

Call JJHCS at 1-800-255-2500 (option 1) between 8:30 a.m. and 8:00 p.m. eastern time, or fax
your order to 1-832-562-2212 or 1-800-997-1122. For more information or product support, call
1-877-ETHICON (384-4266).
Customer support
For product use assistance, clinical guidelines, service and repair, emergency assistance, copy
of 510(k) clearance letter or complaints, please contact our Customer Support Center at
[email protected] or by calling 1-877-ETHICON (384-4266). Our support center is
staffed 24 hours a day, 7 days a week by qualified nurses to answer your product-related questions.
For complete product details, see Instructions for Use. For more information, contact your
local Ethicon representative or call 1-877-ETHICON (384-4266).
9
Instructions for Use
10
11
12
510(k) Clearance Letter
13
14
15
Clinical Evidence
The Global Evidence Database and the Clinical Evaluation Report: PROCEED® Surgical Mesh
(December 4, 2014) were searched for published and unpublished clinical studies of PROCEED Mesh
use for hernia repair. The 15 studies identified are summarized below.
Global Evidence Database

Laparoscopic Ventral Hernia Repair
Berrevoet F, Tollens T, Berwouts L, et al. A Belgian multicenter prospective observational cohort study shows
safe and efficient use of a composite mesh with incorporated oxidized regenerated cellulose in laparoscopic
ventral hernia repair. Acta Chirurgica Belgica. 2014;114(4):233-238.
Summary
This multi-center, prospective, non-controlled study evaluated the results of 210 patients undergoing primary
laparoscopic ventral hernia repair or incisional hernia repair using an intra-abdominal placement of the
PROCEED Mesh (Ethicon Inc., Johnson & Johnson, Somerville, NJ, USA).
At one year, the cumulative incidence of recurrence was 10 cases (n=192, 5.2%), and chronic discomfort or
pain was observed in 4.7% of patients. There were no incidences of conversion to open repair, enterotomy,
mesh infection or mortality. At two years, there was one additional recurrence.
The authors concluded that they had a favorable experience with the PROCEED Mesh in laparoscopic ventral
hernia repair.
Objectives
To evaluate the efficacy and safety of the PROCEED Mesh in laparoscopic ventral hernia repair
Design
This was a multi-center, prospective, non-controlled study.
The primary endpoint was the recurrence rate at 1 year, where recurrence was defined as “any abdominal
wall gap with or without bulge in the area of the midline scar perceptible or palpable by clinical examination.”
Secondary endpoints included postoperative morbidity, including seroma formation, mesh infections and
recurrence after two years.
Subjects
Adult patients undergoing primary laparoscopic ventral hernia repair or incisional hernia repair between
January 2008 and March 2009 in nine centers in Belgium.
Exclusion criteria were hostile abdomen with conversion from a laparoscopic to an open approach,
emergency surgery and repair of a parastomal hernia.
16
Clinical Evidence
(Continued)
Berrevoet F, Tollens T, Berwouts L, et al. A Belgian multicenter prospective observational cohort study shows
safe and efficient use of a composite mesh with incorporated oxidized regenerated cellulose in laparoscopic
ventral hernia repair. Acta Chirurgica Belgica. 2014;114(4):233-238.
Procedures
Patients underwent primary laparoscopic ventral hernia repair or incisional hernia repair using an intra-abdominal
placement of the PROCEED® Surgical Mesh (Ethicon Inc., Johnson & Johnson, Somerville, NJ, USA).
Follow-up was performed 3–6 weeks after surgery and 1 year and 2 years postoperatively.
Results
210 patients were included in the study (113 men and 97 women), of which there were 97 primary ventral
and 103 incisional hernias after prior abdominal surgery, and 28 patients (13.3%) were treated for a recurrent
incisional hernia. The mean age was 60 years.
At 3-6 weeks follow-up, there were 14 clinically palpable seromas without need for treatment.
There were no incidences of conversion to open repair, enterotomy, mesh infection or mortality.
At one year, the cumulative incidence of recurrence was 10 cases (n=192, 5.2%), and chronic discomfort
or pain was observed in 4.7% of patients. At two years, there was one additional recurrence.
Twelve patients were re-operated during the first year due to recurrence (n=7), acute cholecystitis (n=2),
trocar site hernia after gastric bypass (n=1) and pain (n=2).
Conclusions
The authors concluded that they experienced a favorable experience with the PROCEED Mesh in
laparoscopic ventral hernia repair.
17
Clinical Evidence
Clinical Evaluation Report – PROCEED® Surgical Mesh (December 4, 2014)
Laparoscopic Ventral Hernia Repair
Hussain D, Sarfraz SL, Kasmani JA, et al. Laparoscopic repair of ventral hernia. J Coll Physicians Surg Pak.
2012;22(11):683-685.
In a retrospective review with 27 patients followed for 23 months, Hussain (2012) evaluated postoperative
complications after laparoscopic ventral hernia repair. In this study, transfixating sutures and additional tacks
were used for fixation. Primary hernia was diagnosed in 23 patients while 4 patients had recurrent hernias, with a
mean duration of symptoms being 10 ± 11 months (range: 2-48 months). Seven of the 27 patients had risk factors
of hypertension, and three were diabetic. Four additional patients were obese and had ischemic heart disease as
pre-existing comorbidities. After surgery, 3 patients had seromas/hematomas, which resolved with conservative
treatment. No recurrence or wound infections were observed. Pain was reported in 4 patients who improved
after analgesic administration. The authors concluded that laparoscopic repair with PROCEED Mesh was an
appropriate approach resulting in good quality repair and low complication rates.
Khalil M, Mostafa HA, Hassan AEM. Laparoscopic intraperitoneal onlay mesh repair of ventral hernias:
early experience at Sohag University Hospital Egypt. Egypt J Surg. 2012;31(4):141-147.
Khalil (2012) reported a retrospective review including 27 patients followed for 13 months (mean) who underwent
laparoscopic incisional ventral hernia repair. Mesh was fixated with an endoscopic stapler. The objective was
to measure both short- and intermediate-term outcomes, which were evaluated postoperatively by clinical
examination as well as ultrasound for complications or recurrence. No bowel injury or other intraoperative complication
occurred. Seromas (n=5), wound infection (n=1), chest infections (n=2), and recurrence (n=1) were observed. Three of the
seromas were treated conservatively and resolved spontaneously within 2 weeks. The remaining 2 cases required
aspiration and improved after 5 weeks. Though ileus did occur in 2 patients, recovery was achieved with “simple
measures” after 3 days. Seven patients were lost to follow-up after the first two visits at one and weeks post-discharge.
There were no cases of mesh removal due to infection, and the single case of recurrence occurred in a high-risk
morbidly obese patient with pre-existing chronic obstructive airway disease. The authors concluded that
laparoscopic ventral hernia repair with PROCEED Mesh permitted rapid recovery and a low recurrence in short-
and intermediate-term follow-up.
Tollens T, Speybrouck S, Devroe K, et al. Comparison of Recurrence Rates in Obese and Non-Obese Patients
Undergoing Ventral Hernia Repair with Lighter-Weight Partially Absorbable Mesh. Surg Technol Int.
2011;21:140-143.
A retrospective analysis was conducted by Tollens (2011) in 86 obese and non-obese patients using PROCEED
Mesh to laparoscopically repair incisional hernias to compare the recurrence rate in these two patient groups.
Obesity was defined as Body Mass Index (BMI) ≥30 kg/m2. Laparoscopic technique was used in 31 obese and
47 non-obese subjects. Two obese patients and 6 non-obese patients underwent hernia repair with the open
technique. A variety of fixation methods were employed including EMS tackers, PROLENE® Polypropylene
Suture, AbsorbaTack™ Fixation Device, SorbaFix™ Absorbable Fixation System, and ETHICON SECURESTRAP®
Absorbable Strap Fixation Device. Mean follow-up was 14 months, ranging from 7.4 months to 22 months. Tollens
and colleagues reported no wound or mesh infections but did note 4 recurrences among 78 retrospective
cases. The postoperative stay ranged from 0-5 days, and the mean was 2 days. Overall, 12 patients (14%)
developed seromas, 1 (1.2%) cellulitis of the abdominal wall, 1 (1.2%) ileus, and 1 (1.2%) persistence of pain at 1-year
follow up. There were 4 (4.46%) recurrences (2 in patients with ≥30 kg/m2 BMI and 2 in patients with <30 kg/m2
BMI). No wound or mesh infections, bowel obstruction, or enteric fistulas occurred. The study demonstrates the
utility of PROCEED Mesh in ventral hernia repair by a standardized laparoscopic technique or open technique.
The equivalent recurrence rates between the obese and non-obese populations in this study indicated this
mesh possesses adequate strength for use in obese patients.
18
Clinical Evidence
Bucher P, Pugin F, Morel P. Single-port access prosthetic repair for primary and incisional ventral hernia:
Toward less parietal trauma. Surg Endosc. 2011;25(6):1921-1925.
Bucher (2011) examined the use of PROCEED® Surgical Mesh on a new laparoscopic technique with a
single-port access (SPA) for incisional and primary ventral hernia repair in an uncontrolled, prospective trial
including 52 patients. The method of fixation used in this study was absorbable tacks (AbsorbaTack™ Fixation
Device) and absorbable sutures. Patients with umbilical hernias (n=32), incisional hernias (n=14), inguinal hernia
(n=1) and those with hernia of the linea alba (n=1) were included in this study. Follow-up was a mean of 16 months,
ranging from the 3-28 months. SPA repair of primary and incisional ventral hernia was completed in all cases
without conversion to standard laparoscopy. The median (range) hospital stay was 1 day (1-5 days). No intra-
operative complications were noted. Notably, there were no cases of recurrence, 2 cases of seroma (treated
conservatively), and 1 case of pain that resolved spontaneously after 3 months. Per the authors’ conclusions,
SPA ventral hernia repair appears to be safe for experienced SPA surgeons.
Berrevoet F, Fierens K, De Gols J, et al. Multicentric observational cohort study evaluating a composite
mesh with incorporated oxidized regenerated cellulose in laparoscopic ventral hernia repair. Hernia.
2009;13(3):23-27.
Berrevoet (2009) conducted a multicenter, observational, single cohort study in 114 subjects using PROCEED
Mesh fixed with tacks and transfascial sutures per the surgeon’s preference to evaluate outcomes of laparoscopic
ventral hernia repair of primary hernia defects (umbilical, epigastric, and Spigel). Direct follow-up was done at
3 weeks, 3 months, and 6 months postoperatively and then by telephone using a standardized checklist at
12 months and yearly thereafter. The patients were followed for a mean of 27 months (range: 12-38 months) with
outcomes including chronic pain (by oral analgesic use at 6 months), and the incidence of seroma, hematoma,
wound or mesh infection, and recurrence. Four (3.5%) recurrences occurred with 3 of the 4 patients being
reoperated. Twelve (10.5%) patients developed seromas or hematomas, with 4 of the 12 requiring treatment.
Pain lasting greater than 6 months was reported in 2 patients (1.8%). One of these patients had pain at the tack
fixation level and was treated with infiltrations of long-acting anesthetics while the other patient had pain due to
adhesions, which were addressed in re-laparoscopy. An additional patient had urinary retention postoperatively
(no treatment specified). The authors concluded that this study documented a favorable experience using a
large-pore mesh in laparoscopic ventral hernia repair with no major complications related directly to the mesh.
Sodergren MH, Swift I. Seroma formation and method of mesh fixation in laparoscopic ventral hernia repair
– Highlights of a case series. Scand J Surg. 2010;99(1):24-27.
Sodergren (2010) conducted a retrospective case series with 50 patients and 55 cases treated laparoscopically
with PROCEED Mesh or Composix™ Mesh (Bard) fixated by a helical stapling device (ProTack™ 5 mm Fixation
Device). Hernia types treated included epigastric (n=1), lumbar (n=1), umbilical (n=2), parastomal (n=8), and
incisional (n=44). The median operating time was 50 minutes (range 30-120), and the median length of stay was
1 day (range 1-14). One procedure was abandoned due to the size of the hernia. Two (2) patients (3.6%) converted
to open repair, and operative complications were reported in 2 patients (3.6%). Postoperatively, 12 patients
(21.8%) developed minor morbidity, 2 (3.6%) wound infections, 1 (1.8%) was re-admitted due to pain, and
8 (14.5%) developed seromas. The seromas all resolved with conservative treatment. Six patients (10.9%)
had recurrence; however, the authors note that all recurrences were associated with obese patients (mean BMI
37 kg/m2) and potential inadequate stapling – known risk factors. Two of the 6 recurrences were reported in
one patient.
19
Clinical Evidence
Eriksen JR, Poornoroozy P, Jorgensen LN, et al. Pain quality of life and recovery after laparoscopic ventral
hernia repair. Hernia. 2009;13(1):13-21.
Eriksen (2009) conducted a single-arm prospective, multicenter study in 35 patients with ventral hernias to
evaluate pain and other recovery parameters post-laparoscopic hernia repair. PROCEED® Surgical Mesh was
used in all patients. Mesh was fixated laparoscopically by the use of tacks (ProTack™ 5 mm Fixation Device).
Discharge was planned for all patients on postoperative Day 2 with return to normal daily activities/work without
risk. Self-assessment of pain, general wellbeing, fatigue, and quality of life were measured via SF-36 questionnaires.
Patients were also asked to self-report nausea and overall bowel function. All assessments were made on the day
of surgery, and again at Days 1-7, Day 30, and finally at the 6-month time point. All patients were also seen in the
clinic at Day 30 and again at study end where physical examination was made and ultrasound performed. After
one month, 23% of the patients developed seromas, 10% had superficial wound infections, and 6% reported
hematomas. By study end, there was no reported recurrence, and all other complications resolved. The
investigators concluded that laparoscopic ventral hernia repair was associated with considerable postoperative
pain and fatigue in the first postoperative month, prolonging the time of convalescence and significantly
affecting patients’ quality of life up to 6 months postoperatively. Mesh fixation with fibrin glue or other
non-invasive/degradable products seems promising for reducing pain, and it should be investigated in future
randomized trials.
Datta T, Eid G, Nahmias N, et al. Management of ventral hernias during laparoscopic gastric bypass.
Surg Obes Relat Dis. 2008;4(6):754-758.
Datta (2008) evaluated the clinical outcomes of laparoscopic ventral hernia repair after antecolic laparoscopic
gastric bypass in this retrospective analysis of 26 patients (PROCEED Mesh: n=10; primary repair, n=8; hernia
left in situ, n=8). The fixation method for the mesh implant was unspecified tacks. Outcomes were measured
by the incidence of recurrence and other complications. Patients were followed for an average of 14 months
(range: 4-30 months). No complications in the in situ group were noted. Two patients in the primary repair group
developed small bowel obstruction, and both underwent laparoscopic bowel resection and ventral hernia repair
without postoperative complications using PROCEED Mesh. No bowel obstruction, clinical evidence of
recurrence or infection was reported in the original 10 PROCEED Mesh patients. One PROCEED Mesh patient
reported chronic pain at 3 months postoperatively, which was resolved with transection of a single adhesive
band attached to one of the tacks with no adhesions noted to the mesh itself.
Rosenberg J, Burcharth J. Feasibility and outcome after laparoscopic ventral hernia repair using Proceed
mesh. Hernia. 2008;12(5):453-456.
Rosenberg (2008) conducted a retrospective study in 49 patients using PROCEED Mesh fixated with ProTack™
5 mm Fixation Device to determine the feasibility of use in laparoscopic ventral hernia repair. Higher-risk patients
were included in this with 16 patients being obese, 15 were smokers, and 7 had chronic obstructive pulmonary
disease. Hernia types repaired in this study were Spigelian, umbilical, parastomal, incisional, and linea alba. The
incidence of recurrence and postoperative complications constituted the measured outcomes. Patients were
followed for a median of 17 months (range: 3-27 months). The median hospital stay was 1 day. Of the 49 patients,
five developed postoperative complications. One patient developed a pulmonary embolism extending hospital
stay to 37 days; one patient was diagnosed with uncomplicated pneumonia and recovered quickly; an additional
patient developed respiratory unspecified respiratory complications and was hospitalized for 54 days; one
patient had a small bowel perforation during repair of a stomal hernia necessitating re-laparotomy and mesh
removal; the last of the five patients with postoperative complications developed an uncomplicated wound
infection at the trocar site. There were no mesh infections or seromas observed. As there were no mesh
infections or other mesh-related complications, the authors concluded that the use of PROCEED Mesh in
laparoscopic ventral hernia repair was safe and effective even in some of the higher-risk patients who were
obese or who had pulmonary disease.
20
Clinical Evidence
Laparoscopic and Open Ventral Hernia Repair
Moreno-Egea A, Aguayo-Albasini JL, Ballester MM, et al. Treatment of incisional hernias adopting an
intra-abdominal approach with a new low-density composite prosthetic material: Proceed: our preliminary
experience on 50 cases. Surg Laparosc Endosc Percutan Tech. 2009;19(6):497-500.
Moreno-Egea (2009) investigated PROCEED® Surgical Mesh, both in open (20 cases) and laparoscopic
(30 cases) ventral repair with excellent safety results. Tacks (ProTack™ 5 mm Fixation Device) were used to
fixate the mesh. The authors encountered one case of reintervention due to hemoperitoneum caused by
a trocar, and no infections, no seroma, no intestinal occlusion, and no recurrence after 12 months follow-up.
PROCEED Mesh was judged by the authors to be safe and well tolerated during incisional hernia repair.
Open Ventral Hernia Repair

Liu F, Li J. Repair of large abdominal wall defects using the Proceed surgical mesh with open
intra-peritoneum onlay method. Saud Med J. 2011;32(5):504-509.
Liu (2011) reported the use of PROCEED Mesh fixated by the use of interrupted 0 polypropylene sutures in
36 patients undergoing open surgery for large abdominal wall defects. This study included 22 patients with
incisional hernia, 4 with recurrent incisional hernia, 2 with incarcerated incisional hernia, 2 with abdominal wall
defects secondary to metastasized cancer, and 6 with desmoids tumor resections. Assessment was made at
3 weeks, 3 months, and finally at 6 months in the outpatient clinic. The mean total follow-up time was 28 months.
Postoperatively, it was reported that 11 patients (30.6%) developed complications: 6 seromas, 1 minor wound
infection, 1 wound sinus, 2 pulmonary infections, and 1 urinary tract infection. There were no instances of intestinal
fistulas, problems related to intestinal adhesion, chronic wound pain, or mesh infections. No adhesion-related
complications, recurrences, or mesh infections occurred. Liu and colleagues demonstrated that the intra-peritoneal
repair technique for a large abdominal wall defect using PROCEED Mesh was a feasible and safe method in these
patients with no report of major complications.
El-Shafei E. Repair of Congenital and Acquired Abdominal Wall Defects in Infants Using Proceed Surgical
Mesh. Ann Pediatr Surg. 2009;5(1);46-51.
El-Shafei (2009) examined the use of PROCEED Mesh for the repair of abdominal wall defects in infants. In this
study, there were 6 infants with major omphalocele, 5 with ventral hernia, 4 with burst abdomen, and 3 cases of
incisional hernia. A fixation method of continuous PROLENE® Polypropylene Suture or interrupted ETHIBOND
EXCEL® Polyester Suture was used. Outcomes were measured by the incidence of postoperative complications
in this higher-risk population. The follow-up period was a mean of 14.7 months (range: 2-21 months). Complications
included wound infection (4 cases, 2 of which were in cases with burst abdomen), stitch sinus (2), and seroma (8).
The stitch sinus cases responded well to simple excision, and the seromas were successfully evacuated via drain
resulting in complete resolution. All wound infections were managed conservatively and resolved with regular
irrigation and dressing. One patient had skin necrosis, and one died due to a major heart anomaly; neither case
attributed to the mesh device. Based on the study results, the authors concluded that PROCEED Mesh was an
excellent alternative for bridging major congenital and acquiring abdominal wall defects in infants, in which
direct closure could not be achieved, and direct contact between the mesh and the bowel cannot be avoided.*
*Warning: When this mesh is used in infants, children, pregnant women or women planning pregnancies, the surgeon should be aware that this product will not stretch
significantly as the patient grows. For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full instructions for use.
21
Clinical Evidence
Berrevoet F, Murdoch J, Jones P, et al. Open Hernia Repair Surgery Using a Tissue-separating Flat Mesh
(TSM) - 12 Month Patient Reported Outcomes from the International Hernia Mesh Registry (IHMR). Poster
presented at 15th Annual Hernia Repair; March 13-16, 2013; Orlando, FL.
Berrevoet (2013) captured 12-month patient-reported outcomes following implantation with PROCEED Mesh.
The results included 82 patients who underwent open repair (preperitoneal, n=40; intraperitoneal, n=40;
retrorectus, n=1; onlay, n=1). Of these, 4.9% were umbilical, and 95.1% were ventral; 82.9% were fixated with sutures.
At 12 months post-op, 30.9% of patients reported symptomatic pain compared to 62.3% pre-surgery. The overall
mean pain and movement limitation scores at 12 months had significantly decreased compared to pre-surgery.
Complications at 12 months included recurrence (3.7%), seroma (6.1%), and hematoma (4.9%). No mesh infections
were reported. Longitudinal data provided by the IHMR showed a low recurrence rate for open hernia repair
using PROCEED Mesh. The 12-month post-surgery patient-reported Carolinas Comfort Scale™ data indicated a
statistically significant improvement in pain and movement availability, thereby suggesting the success of open
hernia repair using this mesh.
Laparoscopic Inguinal Hernia Repair

Wenbin L, Yuzhou L. The application of modified transabdominal preperitoneal prosthetic laparoscopic
hernioplasty. Surg Laparosc Endosc Percutan Tech. 2010;20(2):e57-e59.
Wenbin (2010) investigated a modified trans-abdominal pre-peritoneal technique, also laparoscopic, for inguinal
hernia repair in a large, prospective uncontrolled trial including 1,100 patients. This technique, using PROCEED®
Surgical Mesh fixated by absorbable sutures and an endostapler, was shown to be safe with 0.9% recurrence
rate, no infections, no migrations, and no adhesive ileus. A total of 1,002 (95%) patients were discharged within
48 hours and back to normal activity within 3 days. Other patients were all back to normal activities within
14 days. The authors reported that 902 (82%) of patients required only over-the-counter analgesics postoperatively
with 198 patients (18%) requiring oral analgesics for 2 to 21 days, and 10 (0.9%) patients requiring analgesic medication
for chronic pain. Two (2) cases of seroma and 10 cases of urinary retention were noted. Wenbin and colleagues
posited that the modified laparoscopic hernioplasty is a safe and efficacious treatment option for primary
inguinal hernia. The technique shows less operative time, rapid rehabilitation, less overall complications and
discomfort, which lead to lower costs in this patient population.
Finley DS, Rodriguez E, Ahlering TE. Combined inguinal hernia repair with prosthetic mesh during
transperitoneal robot assisted laparoscopic radical prostatectomy: A 4-year experience. J Urol.
2007;178(4):1296-1300.
Finley (2007) evaluated the use of 3 types of meshes (PROCEED Mesh, n=10; Marlex® Mesh, n=19; polypropylene
cone mesh plug, n=19) in inguinal herniorrhaphy procedures concurrent with robot-assisted laparoscopic radical
prostatectomies (RALP) versus historical controls. Fixation devices included DEXON™ S Suture or Tevdek®
Non-Absorbable Suture (PROCEED Mesh, Marlex® Mesh) and ProTack™ 5 mm Fixation Device followed by
suture in the case of the polypropylene cone mesh plug. Patients were assessed for postoperative complications
for a median of 15.3 months (range: 1 week to 4.3 years). During the study, no recurrence was noted. One patient
developed postoperative urine leakage and underwent subsequent revision (mesh product unidentified). No
significant between-group differences in smoking history, analgesic use, blood loss, duration of hospital stay,
or complications was found between the historic controls and mesh groups. The authors concluded that
simultaneous repair of inguinal hernias during transperitoneal RALP was not only technically feasible but also
effective without increased complications attributable to its application.
Open Inguinal Hernia Repair

No studies were found.
CR# 055580-160627
22
References
1. Bhende S. Study Report for Antibacterial Efficacy Evaluation of PROCEED Surgical Mesh using Parallel Streak Method. Jan. 18, 2018. Ethicon, Inc.
2. Vailhe E. Mesh Competitor Testing, Version 1. AST-2015-0024. July 21, 2015. Ethicon, Inc.
3. Cobb WS, Kercher KW, Heniford BT. The argument for lightweight polypropylene mesh in hernia repair. Surg Innov. 2005 Mar;12(1):63-69.
4. Cobb WS, Warren JA, Ewing JA, et al. Open Retromuscular Mesh Repair of Complex Incisional Hernia: Predictors of Wound Events and Recurrence.
J Am Coll Surg. 2015;220:606-613.
5. PROCEED® Surgical Mesh. Instructions for Use. Ethicon Inc. Somerville NJ. 2014.
6. Klosterhalfen B, Junge K, Klinge U. The lightweight and large porous mesh concept for hernia repair. Expert Rev Med Devices. 2005;2(1)103-107.
7. Amid PK. Classification of biomaterials and their complications in abdominal wall hernia surgery. Hernia. 1997;1:15-21.
8. Deeken CR, Abdo MS, Frisella MM, Matthews BD. Physicomechanical evaluation of absorbable and nonabsorbable barrier composite meshes
for laparoscopic ventral hernia repair. Surg Endosc. 2011 May;25(5):1541-1552.
9. Rosenberg J, Burcharth J. Feasibility and outcome after laparoscopic ventral hernia repair using Proceed mesh. Hernia. 2008;12:453-456.
10. Berrevoet F, Murdoch J, Jones P, et al. Open hernia repair surgery using a tissue-separating flat mesh (TSM)—12 month patient reported outcomes
from the International Hernia Mesh Registry (IHMR). Poster presented at 15th Annual Hernia Repair; March 13-16, 2013; Orlando, FL.
11. Berrevoet F, Tollens T, Berwouts L, et al. A Belgian multicenter prospective observational cohort study shows safe and efficient use of a composite
mesh with incorporated oxidized regenerated cellulose in laparoscopic ventral hernia repair. Acta Chirurgica Belgica. 2014;114:233-238.
12. Hutchinson RW, Chagnon M, Divilio LT. Preclinical Abdominal Adhesion Studies With PROCEED* Surgical Mesh. 2000. Ethicon, Inc.
13. Bhende S. Study Report for Antibacterial Efficacy Evaluation of PROCEED Surgical Mesh using Parallel Streak Method. Jan. 18, 2018. Ethicon, Inc.
©2018 Ethicon US, LLC. All rights reserved. 057206-180511
23

PROCEED® Surgical Mesh

Uploaded by

Copyright:

Available Formats

PROCEED® Surgical Mesh

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

PROCEED® Surgical Mesh

Uploaded by

Copyright:

Available Formats

Value Analysis Committee

Third-party trademarks used herein are trademarks of their respective owners.

PROCEED® Surgical Mesh

Designed for Strength

300 252 mmHg

Open repair Laparoscopic repair

*Shown in a preclinical study

Supports Comfortable Healing

62% 3.5 6 Months^

Results from a laparoscopic ventral hernia repair study showed low

Postoperative Complication 2 Year Follow-Up Rate

Pain or discomfort 4.7%

*Data from an animal study

Immediately Post Implantation 6 Hours Post Implantation

Available in a Range of Sizes

Indications for use

For complete indications, warnings,

Mesh Conversion Chart

PCDR1 7.5 cm x 15 cm 5954460 5955460 SYM1510 PCO1510X

PCDN1 10 cm x 15 cm 5954460 5955460 SYM1510 PCO1510X

PCDM1 15 cm x 15 cm 5954600 5955600 SYM15 PCO15X

PCDG1 15 cm x 20 cm 5954680 5955680 SYM2015 PCO2015X

PCDH1 20 cm x 25 cm 5954810 5955810 SYM2520 PCO2520X

PCDJ1 20 cm x 30 cm 5954113 5955113 SYM3020 PCO3020X

PCDT1 26 cm x 34 cm 5954113 5955113 SYM3728 PCO3728X

PCDW1 25 cm x 35.5 cm 5954113 5955113 SYM3728 PCO3728X

PCDL1 30.5 cm x 30.5 cm 5954124 5955124 SYM4024E PCO3728X

Electronic ordering options

Order 360™: order360.jnjgateway.com

Global Healthcare Exchange: ghx.com

Electronic Data Interchange

Nonelectronic/Manual ordering options

Instructions for Use

Instructions for Use

Instructions for Use

510(k) Clearance Letter

510(k) Clearance Letter

510(k) Clearance Letter

Global Evidence Database

Open Ventral Hernia Repair

Laparoscopic Inguinal Hernia Repair

Open Inguinal Hernia Repair

©2018 Ethicon US, LLC. All rights reserved. 057206-180511

You might also like